1 Anti-in¯ammatory non steroidal drugs releasing NO (NO-NSAIDs) are a new class of antiin¯ammatory drugs to which has been added an NO-releasing moiety. These compounds have been shown to retain the anti-in¯ammatory, analgesic and antipyretic activity of the parent compound but to be devoid of gastrointestinal (GI) toxicity. 2 Freund's adjuvant (FA) arthritis was induced in rats by a single intraplantar injection into the right hindpaw of 100 ml of mycobacterium butirricum (6 mg ml
Introduction
Rats injected into the hindpaw with a mixture of Mycobacterium butirricum emulsi®ed in light mineral oil develop a severe polyarthritis which shares some features in common with human rheumatoid arthritis (RA), such as swelling of the extremities, cartilage degradation, loss of joint function and lymphocyte in®ltration into diseased joints. This model was originally described more than 30 years ago (Pearson et al., 1961; Pearson, 1963) and is still the most widely used assay to identify chemical agents having a potential therapeutic ecacy in RA. Furthermore, this model allows evaluation of analgesic activity of antirheumatic drugs in pathologically induced pain. Indeed, it has been shown that between days 14 and 21 following arthritis induction, a clear hyperalgesic response is present both in the injected and in the controlateral (non injected) hindpaw. This hyperalgesic response has been shown to be reduced by non-steroidal anti-in¯ammatory drugs (NSAIDs) .
NSAIDs are the mainstay in the treatment of pain and in¯ammation. Patients with diseases such as rheumatoid arthritis are prescribed large amount of NSAIDs. However, one of the major contraindications to NSAID therapy are the GI side eects, which can cause ulceration as well as GI bleeding. Recently, we have shown that a nitrosylated derivative of naproxen, NO-naproxen, retains the therapeutic eects of the native compound, without causing GI damage (Davies et al., 1997) . The eect of NO-naproxen, as well as of other members of this family of NO-releasing compounds, has been attributed to COX inhibition and NO released (Wallace & Cirino, 1994) .
Nitric oxide is produced constitutively by endothelial nitric oxide synthase or by neuronal nitric oxide synthase. Moreover, a large amount of nitric oxide is produced by inducible nitric oxide synthase upon stimulation with bacterial products and cytokines, including IFN-g, TNFa and IL-1 (Moncada & Higgs, 1993; Feldman et al., 1996) . As such, NO has emerged as an important endogenous mediator of in¯ammation and immune response (McCartney-Francis et al., 1993; StefanovicRacic et al., 1994a) . NO is produced by rodent synoviocytes and macrophages, by rodent and human neutrophils, chondrocytes and mast cells and by human synovial tissues obtained from RA and ostheoarthritic patients (Charles et al., 1993; Barnes & Liew, 1994; Stefanovic-Racic et al., 1994b; McInnes et al., 1996) . Up until now, there has been no evidence of the bene®cial eect of NO-NSAIDs on immunologic in¯ammation; however, a member of this class of compounds, NO-¯urbiprofen, has been shown to interfere with iNOS induction (Cirino et al., 1996) .
In order to evaluate whether NO-NSAIDs could aect also immunocompetent cells involved in in¯ammation, in the present study we evaluated the eect of NO-naproxen and naproxen on an experimental model of immunologic in¯am-mation.
Methods

Induction of Freund's adjuvant arthritis
Male, Lewis rats (120 ± 140 g) were housed in propylene cages with food and water ad libitum. The light cycle was automatically controlled and the room temperature thermostatically regulated to 21+18C. Prior to the start of the experiment, animals were housed under these conditions for 6 ± 8 days. Arthritis was induced by injecting into the right hindpaw 100 ml of Mycobacterium butirricum (6 mg ml 71 ) suspended in complete adjuvant. Hindpaw volume was measured by the mean of an hydroplethysmometer (Ugo Basile, Italy) immediately before arthritis induction (basal value) and 3, 7, 11, 14, 17, 21 days thereafter, for both the injected and controlateral hindpaw. Hindpaw swelling is expressed as increase in hindpaw volume in ml calculated by subtracting the basal value from the hindpaw volume measured at all times considered. Either naproxen (1, 3 and 10 mg kg 71 ) or equimolar doses of NO-naproxen (1.5, 4.5 and 16 mg kg 71 ) were dissolved in dimethylsulfoxide (DMSO) and suspended in carboxymethylcellulose (CMC) 0.2% w v
71
. Drugs were given daily by oral gavage to rats following two regimen of dosing: (i) preventive, from day 1 to 21 and (ii) therapeutic, from day 7 to 21. Control groups received the same volume of DMSO plus CMC 0.2% w v 71 by oral gavage. Higher doses of naproxen could not be tested due to the elevated toxicity (we were not allowed by the veterinarian to study the eect of 30 mg kg 71 of naproxen).
Randall Selitto assay
Randall Selitto assay was performed on both hindpaws at day 15 and 21 (Randall & Selitto, 1957) . Brie¯y, pressure was applied through a tip to the plantar surface of the hindpaw at a constant rate using an analgesiometer (Ugo Basile, Comerio, Italy) to the point at which the animal struggled, squealed or attempted to bite. The test was run by an observer unaware of the treatment. The force (expressed in grams) at which the animal began to struggle was assumed to represent the nociceptive threshold and served as the end point.
T cell proliferation assay
Draining lymph nodes (DLN) were removed from controlateral or injected hindpaws of Freund's adjuvant (FA)-treated rats at the end of each experiment at day 22 as previously described (Ianaro et al., 1994 
Cell FACS analysis
Cytokine, IL-1b and TNFa plasma levels
Cytokine levels were assayed in plasma samples using a rat IL1b ELISA kit (Endogen, U.S.A.) and TNFa ELISA kit (Genzyme, Cambridge, MA, U.S.A.) following the manufacturer's instructions. TNFa detection limit is 25 pg ml 71 , inter/ intra assay variation is 510%. Cross reactivity with TNFa is 100%, TNFb 50.01%; TNFrI50.01%; TNFrII 50.01%. IL1b detection limit is 30 pg ml 71 ; inter/intra assay variation is 510%. Cross reactivity with IL-1b 100%. IL-1a 50.01% and IL-2 50.01%.
Statistical analysis
Data are expressed as mean+s.e.mean. (n=6 ± 10) and statistical signi®cance was evaluated by using ANOVA followed by Dunnett's test. For the statistical determination a statistical computerised package, INSTAT (Graphpad Software, U.S.A.) was used. A value of P50.05 was considered signi®cant.
Drugs
Mycobacterium butirricum, Freund's adjuvant (DIFCO), concanavalin A (ConA) were obtained from Sigma (Milan, Italy). Rabbit anti-rat CD4, CD8 and CD25 (IL-2R) monoclonal antibodies were from Pharmingen (San Diego, CA, U.S.A.). Fluorescein isothiocyanate (FITC)-conjugated anti-rabbit monoclonal antibody was purchased from Sigma (Milan, Italy). Culture medium was RPMI containing 10% v v 71 foetal calf serum, L-glutamine (2 mM), penicillin (100 u ml 71 ), streptomycin (100 mg ml
71
), 2-mercaptoethanol (50 mM) were purchased from Sigma (Milan, Italy). [ 3 H]-thymidine was purchased from Amersham (Milan, Italy). Naproxen was obtained from Sigma (Milan, Italy) NO-naproxen was a generous gift of NicOx SA Sophia Antipolis (France).
Results
Adjuvant arthritis
Swelling in the controlateral hindpaw was signi®cantly reduced by naproxen 10 mg kg 71 and by NO-naproxen 16 mg kg 71 using both regimens of dosing (day 1 ± 21 and 7 ± 21).
Controlateral hindpaw volume at day 14 following the dosing regimen day 1 ± 21 was: 0.62+0.05 ml for control, 0.43+0.04 ml for naproxen 10 mg kg 71 (n=10; P50.05) and 0.39+0.04 ml for NO-naproxen 16 mg kg 71 (n=10; P50.05). NO-naproxen (1.5 mg kg
71
) and naproxen (1 mg kg 71 ) did not inhibit oedema formation and paw volume at day 14 i.e. 0.54+0.09 ml (n=6; P40.05) and 0.60+0.08 ml (n=6; P40.05) for naproxen and NO-naproxen respectively. Similarly, at day 14 following the regimen dosing day 7 ± 21, the hindpaw volume of the controlateral hindpaw in control rats was 0.65+0.04 ml while that of naproxen and NOnaproxen treated animals was 0.43+0.08 ml (n=10; P50.05) and 0.35+0.04 ml 71 (n=10; P50.05), respectively. The doses of NO-naproxen 1.5 mg kg 71 and naproxen 1 mg kg 71 were ineective and the hindpaw volumes achieved were 0.58+0.05 ml (n=6; P40.05) and 0.60+0.07 ml (n=6; P40.05), respectively.
Randall Selitto pain assay
As shown in Figure 1a , treatment with naproxen and NOnaproxen from day 1 ± 21 caused an increase in the threshold of nociception of arthritic rats in the injected hindpaw compared to control group. The NO-naproxen eect was present both at day 15 and 21, while naproxen resulted active only at day 15 and at the highest dose tested (10 mg kg 71 ). The eect in controlateral hindpaw is summarized in Figure 1b . Figure 2a shows the analgesic eect in the injected hindpaw following treatment from day 7 ± 21 with both naproxen and NO-naproxen. NO-naproxen caused analgesia at the doses of 4.5 and 16 mg kg 71 whilst naproxen was active only at the highest dose used (10 mg kg 71 ). In the controlateral hindpaw, following treatment from day 7 ± 21, the analgesic eect was not signi®cant with both NO-naproxen and naproxen ( Figure  2b ). Naproxen and NO-naproxen at doses of 1 mg kg 71 and 1.5 mg kg 71 respectively were ineective in both protocols.
TNFa and IL-1b plasma levels
Increased plasma levels of IL-1b and TNFa observed in arthritic rats at day 21 were signi®cantly reduced following treatment with NO-naproxen (16 mg kg 71 ) only at the regimen dosing 1 ± 21 (Figure 3a) . Conversely, following treatment with naproxen (10 mg kg 71 ), at the same dosing regimen, there was a signi®cant reduction in IL-1b plasma levels only (Figure 3b ). Thymidine uptake assay T cells were incubated for 24, 48 and 72 h with ConA (0.5 ± 5 mg ml 71 ). The dose response preliminary study showed that maximal labelled thymidine accumulation was achieved for DLN T cells isolated from lymph nodes of the injected hindpaw at the 48 h point and at 72 h for DLN T cells isolated from lymph nodes of the controlateral hindpaw using a dose of ConA of 5 mg ml 71 . Thus ConA at a dose of 5 mg ml 71 and the two time points were selected for the study. As shown in Figure 4a naproxen, following treatment from day 1 ± 21, caused a dose dependent decrease in labelled thymidine uptake following in vitro stimulation with ConA of DLN T cells isolated from the controlateral hindpaw. Conversely NO-naproxen (4.5 mg kg 71 ) inhibited T cell proliferation to the same extent as naproxen (10 mg kg 71 ) (Figure 4a ). Following treatment from day 7 ± 21 ( Figure 4b ) DLN T cells isolated from the controlateral hindpaw of rats treated with naproxen showed an inhibition only at the highest dose tested (10 mg kg 71 ). Similarly NO-naproxen signi®cantly reduced DLN T cells proliferation only at 16 mg kg 71 . A similar study was conducted on DLN T cells isolated from the injected hindpaw as shown in Figure 5 . Naproxen as well as NO-naproxen following treatment from day 1 ± 21 ( Figure 5a ) signi®cantly reduced thymidine uptake. However, NO-naproxen caused a more marked inhibition of T cell proliferation when compared to naproxen. Following treatment from day 7 ± 21 (Figure 5b ), naproxen caused thymidine uptake inhibition only at the highest dose (10 mg kg 71 ) while NO-naproxen was active at both 4.5 and 16 mg kg 71 .
FACS analysis
IL-2 receptor (CD25 evaluation)
The IL-2 receptor evaluation was performed on day 21 e.g. on DLN T cells isolated at the end of both treatments (day 1 ± 21 and 7 ± 21) with both naproxen (10 mg kg 71 ) and NO-naproxen (16 mg kg
71
). As shown in Figure 6a , following FA administration there was a clear increase in the per cent of IL-2R positive cells, signi®cantly prevented by treatment with both naproxen and NO-naproxen given at dosage regimen 1 ± 21. However, when the data were expressed as mean intensity¯uorescence (MIF %), that can be interpreted as a measure of the receptor number expressed on the cell, both the therapeutic (day 7 ± 21) ) following oral treatment either from day 1 ± 21 or from day 7 ± 21 on TNFa plasma levels. *P50.05; **P50.01 signi®cantly dierent versus FA rats. #P50.001 signi®cantly dierent versus naõÈ ve animals. and the preventive treatment (day 1 ± 21) with both NOnaproxen and naproxen signi®cantly reduced receptor expression on cell surface. (Figure 6b) . Surprisingly the treatment with NO-naproxen (day 1 ± 21) reduced receptor expression levels signi®cantly below the control value (Figure 6b ).
Discussion
Nonsteroidal antiin¯ammatory drugs are the most widely used drugs in the treatment of pain and in¯ammation associated with several immunological and non-immunological diseases. However, their use is strongly limited by adverse GI eects. Recently, NO-NSAIDs, a novel class of anti-in¯ammatory drugs, presenting a nitric oxide releasing moiety, have been shown to retain the classic therapeutic pro®le of native compounds, such as the ability to inhibit in¯ammatory response, nociception and fever, but to spare the GI tract (Wallace & Cirino, 1994; Davies et al., 1997; Wallace et al., 1997) . This particular pro®le has been attributed to the ability of these compounds to release discrete amounts of nitric oxide.
Inducible nitric oxide synthase (iNOS) has been proposed to be at the interface between the innate and the adaptive immune system; there is evidence that NO produced by activated macrophages can restrict T cell expansion (Gregory et al., 1993 , Wei et al., 1995 . NSAIDs have been shown to reduce spleen lymphocyte proliferation and, in particular, indomethacin has been shown to inhibit T cell proliferation (Waltz et al., 1971; Bayer & Beavan, 1979; Seng et al., 1990) .
The observation that T cells in®ltrate the rheumatoid synovium was originally made by van Boxel & Paget in 1975 and since then T cell activation has been widely studied and recognized as a key feature of RA (Firstein & Zvai¯er 1990; Panayi et al., 1992; Van den Berg, 1998) . Nearly 45% of T cells, following a brief transit of about 30 min in the bloodstream, are carried from the blood directly to the spleen where they reside for approximately 5 h. However, an almost equal number of lymphocytes (42%) leave the spleen to go to the lymph nodes where they reside for about 12 h. On the basis of the above observation, we have studied T cell activation using T cells isolated from peripheral draining lymph nodes of arthritic rats. Rat adjuvant arthritis is believed to be the result of a sequence of immunopathologic events involving sensitization to antigen, proliferation of immunocompetent cells, cellular hypersensitivity and mediator release. This cascade of events allows a distinction between a primary and a secondary in¯ammatory response. To characterize the pharmacological pro®le of these drugs we have used two regimen of dosing, one prophylactic (day 1 ± 21) and a second therapeutic (day 7 ± 21), by starting the treatment the same day of FA induction (day 1) or 7 days thereafter, respectively. Under our experimental conditions, both NO-naproxen and naproxen not only reduced the secondary in¯ammation but also modulated T cell proliferative response. T cells isolated from FA rats, once challenged with ConA in vitro, showed a signi®cant increase in proliferation as measured by the labelled thymidine incorporation assay. Interestingly, while thymidine incorporation by T cells isolated from FA rats injected hindpaw was over 100,000 c.p.m., for the controlateral hindpaw it was around 60,000 c.p.m., already underscoring a dierence in activation between T cells derived from lymph nodes interested either in the primary (injected hindpaw) or secondary lesion (controlateral hindpaw). In T cells, isolated from either the injected hindpaw or controlateral hindpaw, about 90% of inhibition of proliferation induced by ConA was achieved with a dose of NO-naproxen of 4.5 mg kg
71
, whilst naproxen showed comparable activity only at the highest dose tested (10 mg kg 71 ). These data imply that both NO-naproxen and naproxen modulate the secondary lesion T cell-dependent response in a therapeutic fashion, and suggest that the eect of both drugs is dependent upon a direct action on immunocompetent cells and not a consequence of inhibition of the primary in¯ammatory response.
NaõÈ ve T cells, upon activation, have to re-enter the cell cycle and rapidly divide. Their proliferation and dierentiation is driven by interleukin-2. To further characterize the mechanism of action of drugs studied, we have evaluated whether the reduction in T cell proliferation was paralleled by a down regulation of interleukin-2 receptor expression on cell surface. Our results clearly show that in arthritic rats, the increased T cell activation was paralleled by increased IL-2R expression on the cell surface as compared to naõÈ ve rats. Following treatment with either naproxen or NO-naproxen, IL-2R expression on the T cell surface was signi®cantly reduced. Interestingly, when data were expressed as mean intensity¯uorescence percentage (MIF %), which can be interpreted as a measure of the number of receptors expressed on the cells, we found that both treatment regimens (day 1 ± 21 and 7 ± 21) with either naproxen or NO-naproxen reduced the number of IL-2 receptors expressed. In addition, treatment with NO-naproxen from day 1 ± 21 caused a reduction of MIF % (e.g. receptor number) to IL-2R levels present in T cells of naõÈ ve animals.
Production of IL-1b and TNFa is known to be a key feature in rheumatoid arthritis. In particular speci®c antibodies to TNFa or its receptors have been shown to be eective in patients with active RA (Kavanaugh, 1998; Moreland, 1998) . We found that NO-naproxen at a dose of 16 mg kg 71 (regimen dosing 1 ± 21) reduced signi®cantly both TNFa and IL-1b plasma levels in FA rats whilst naproxen (10 mg kg 71 ) signi®cantly reduced IL-1b but not TNFa levels.
It has been shown that macrophages regulate T cell function through NO production (Wei et al., 1995; Klimiuk et al., 1999) . Thus, it is likely that the increased eect on T cells of NO-naproxen could be due to the introduction of the NO moiety. In addition introduction of the NO-moiety did not modify the pharmacological pro®le of the compound on classical parameters such as in¯ammation and pain. Indeed, both naproxen and NO-naproxen, tested at equimolar doses, have the same ability to inhibit oedema formation. Concerning nociception, both NO-naproxen and naproxen following treatment from day 1 ± 21 reduced nociception in both injected (primary lesion) and controlateral hindpaw (secondary lesion). Interestingly, NO-naproxen at the dose of 4.5 mg kg
showed an analgesic eect comparable to naproxen 10 mg kg
. These data cannot be due to a dierent pharmacokinetic pro®le since it has been shown that following oral administration of NO-naproxen, plasma levels of parent compound, naproxen, are lower than those achieved after oral administration of an equimolar dose of naproxen (Davies et al., 1997) .
In conclusion our data demonstrate that naproxen and its nitrosylated derivative, NO-naproxen, reduce nociception and in¯ammation associated to arthritis. Both compounds interfere with T cell activation, a key event for the spreading of this disease. In addition NO-naproxen, has a comparable antiin¯ammatory eect but interferes to a larger extent with cellular mechanism involved in T cell activation in rat adjuvant arthritis.
